

NHS Borders
Education Centre
Borders General Hospital
Melrose
Roxburghshire
TD6 9BD
01896 825545
foi.enquiries@borders.scot.nhs.uk



Freedom of Information request 88-20

Request & Response

1. How many patients with cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?

There have been no patients treated with cutaneous squamous cell carcinoma in this time period.

2. How many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma have you treated [eg surgery, chemotherapy or radiotherapy] in the past 3 months?

There has been <5 patients treated with metastatic or locally advanced cutaneous squamous cell carcinoma in this time period.

3. Of these how many are not candidates for curative surgery or curative radiation?

There has been <5 patients not candidates for curative surgery or curative radiation.

- 4. In the past 3 months, how many adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation have you treated with the following;
 - Libtayo (cemiplimab)
 - Non curative surgery only
 - Non curative surgery + chemotherapy*
 - Non curative surgery + radiotherapy
 - Non curative surgery + chemotherapy* + radiotherapy
 - Chemotherapy* only
 - Chemotherapy* + radiotherapy
 - Non curative radiotherapy only
 - No treatment
 - Palliative Care / Best Supportive care
 - Other [please state]

*chemotherapy such as cisplatin, doxorubicin, 5-fluorouracil (5-FU), capecitabine, topotecan, or etoposide

There has been <5 patients treated with Cemiplimab.

5. Does your trust treat adult multiple myeloma [MM]? - if you refer your multiple myeloma patients to another centre, please state which.

Yes.

- 6. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following:
 - Bortezomib [Velcade] 7
 - Carfilzomib [Kyprolis] 0
 - Ixazomib [Ninlaro] <5
 - Lenalidomide [Revlimid] 24

- Daratumumab [Darzalex] <5
- Melphalan, prednisolone and thalidomide (known as MPT) <5
- Cyclophosphamide, thalidomide and dexamethasone (known as CTD) <5
- Pomalidomide [Imnovid] <5
- 7. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?

If possible how many CLL patients treated were new to therapy in the past 3 months?

NHS Borders have treated 17 patients in the last 6 months for chronic lymphocytic leukaemia (CLL).

- 8. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following:
 - Fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (known as FCR) <5
 - Bendamustine and rituximab (known as BR) <5
 - Ibrutinib [Imbruvica] 12
 - Chlorambucil 0
 - Venetoclax <5
 - Obinutuzumab <5
 - Idelalisib 0
 - Fludarabine and rituximab (known as FR) 0
 - High-dose prednisone and rituximab 0
 - Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) 0
 - Alemtuzumab (Campath) with rituximab 0

As the number of events in some areas are very small and in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the ISD Statistical Disclosure Control Protocol.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **88-20** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.